BioVex
ExitedFDA-approved virus engineered to specifically kill cancer cells
Total raised
€84M
€84,036,363
Funding rounds
3
Investors
13
distinct backers
Active since
2003-09
latest 2009-10
Funding by year
EUR raised per yearFunding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2009-11-01 | Series D+ | €27M | Morningside Group,Sectoral Asset Management,Ventech,Ysios Capital | View deal → |
| 2009-03-01 | Series D+ | €36M | Innoven Partners,New Science Ventures,Omnes Venture Capital,Scottish Equity Partners | View deal → |
| 2003-10-01 | Series C | €20M | ABN AMRO,Avalon Ventures,CLSA,LDC,Temasek | View deal → |
Exit
Type
acquisition
Date
Dec 2010
Value
€909M
Acquiror
Amgen (United States Thousand Oaks)